Clinical trials: Neurotrophic Keratitis
Neurotrophic Keratitis
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
- Trial name
- NCT07568730
- Testing
- Lacripep, Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- TearSolutions, Inc.
Neurotrophic Keratopathy
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for mean change from baseline in corneal fluorescein staining in subjects with Stage 1…
- Trial name
- NCT04957758
- Testing
- OC-01 (varenicline) nasal spray 1.2 mg/ml
- Where
- 31 sites in United States
- Volunteers
- 113 people
- Sponsor
- Oyster Point Pharma, Inc.
Corneal Disease, Neuropathy
QST for Corneal Nerve Function
This study is designed to learn more about the impact different types of stimuli, such as heat, cold and vibration, can have on ocular pain response. This is called quantitative sensory testing (QST).
- Conditions
- Corneal Disease, Neuropathy, Dry Eye Disease, Neurotrophic Keratitis
- Trial name
- NCT05758753
- Testing
- Quantitative Sensory Test
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Dry Eye
Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study
patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye
- Trial name
- NCT07566975
- Testing
- Cyclosporine ophthalmic solution 0.1%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Neuro-Ophthalmology of Texas
Ocular Surface Disease, Neurotrophic Keratopathy Stage 1
Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency
STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.
- Trial name
- NCT07502378
- Testing
- Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of South Florida
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A